Actively Recruiting
Evaluation of HMB-Enriched Amino Acid Supplement Effects on Muscle Loss and Recovery in Patients With Alcoholic Liver Disease and COVID-19 Pneumonia
Led by The Cleveland Clinic · Updated on 2026-09-25
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients who have both COVID-19 pneumonia and alcoholic liver disease ALD, focusing on how the illness progresses and whether a supplement called beta-hydroxy beta-methyl butyrate HMB can help. HMB is a special amino acid that is known to support muscle growth and improve immune function. The study aims to see if HMB can prevent breathing problems, reduce illness severity, and improve recovery and survival in these patients. Participants are randomly assigned to one of two groups one group receives the HMB-enriched amino acid supplement, while the other receives a balanced amino acid mixture as a comparison. Both supplements are taken daily for 90 days. The study uses a parallel design with quadruple masking to keep participants and researchers unaware of group assignments. During the study, participants will be monitored for changes in muscle mass from the start to day 90 and tracked for any hospital admissions during this time. Researchers will assess muscle mass and overall health at baseline and at the end of the 90 days. The trial is sponsored by The Cleveland Clinic and will continue through December 2028.
CONDITIONS
Brief Title
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
Research Team
A
Annette Bellar, MSLA
A
Alina Tuladhar, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here